FIGUR8

Objective musculoskeletal health assessment powered by wearable biosensors and AI

Specialty Solutions Growth Series A (USD 44.1M total raised)

Overview

FIGUR8 is a healthcare technology company that transforms musculoskeletal (MSK) care through objective, data-driven biomechanical assessment. Founded in 2016 as an MIT spin-off, the company developed the bioMotion Assessment Platform (bMAP) -- an FDA-registered system that replaces subjective clinical assessments with precise, measurable metrics using wearable sensors and AI.

The platform captures 71 clinically relevant MSK biomarkers across five targeted assessments and delivers lab-grade biomechanics data in clinical settings. FIGUR8 is focused on the workers' compensation market, where its technology drives significant cost savings by reducing recovery times and re-injury rates. Clinical outcomes include 35% faster recovery (56 vs. 85 days) and approximately USD 9,800 in cost savings per patient through more precise care delivery.

The company serves physical therapy practices, workers' compensation payers, occupational medicine physicians, employers, and sports organizations across North America.

Products & Services

bioMotion Assessment Platform (bMAP)

FDA-registered core platform that captures 71 clinically relevant MSK biomarkers across five targeted assessments: neck, low back, knee, lower body screen, and upper extremity endurance. Uses wearable Inertial Measurement Units (IMUs) and Surface Mechanomyography (sMMG) sensors combined with cloud-based analytics and AI/machine learning.

Key Features

Lab-grade biomechanics data measuring joint range of motion, muscle function, movement symmetry, and neuromuscular coordination
Five targeted assessment modules covering the most common MSK injury sites
Cloud analytics dashboard for clinicians, payers, and employers
HIPAA, GDPR, FCC, and HITRUST certified

Target Users: Physical therapists, occupational medicine physicians, workers' compensation payers, employers

Recovery Indicator

Clinically validated AI-driven tool launched July 2025 that classifies patients into recovery groups (Unlikely, Possible, or Probable recovery) based on biomechanical biomarkers. Identifies when patient movement biomarkers stabilize, often ahead of traditional recovery timelines, enabling earlier return to function.

Key Features

AI-based classification of recovery likelihood
Uses biomechanical biomarkers from bMAP assessments
Supports treatment decisions and claims management

Target Users: Workers' compensation case managers, physical therapists, payers

MovementMemo

Generative AI documentation tool launched January 2025 built on the bMAP platform. Enables more efficient care documentation and can reduce recovery times by 20-50% compared to traditional methods.

Key Features

AI-generated clinical documentation from bMAP assessment data
Reduces documentation burden on clinicians
Integrates with existing clinical workflows

Target Users: Physical therapists, clinical staff

At a Glance

Founded: 2016
Headquarters: Boston, Massachusetts, USA
Employees: 11-50
Funding: Series A (USD 44.1M total raised)

Category & Focus

Category: Specialty Solutions
Subcategories: Workers' Compensation Technology Musculoskeletal Assessment Wearable Sensors Clinical AI
Insurance Verticals: Workers Compensation
Target Customers: Carriers, TPAs, Employers